Table 1 Characteristics of healthy controls and transplant patients
Healthy controls (N = 27) | Transplant patients (N = 36) | |
|---|---|---|
Age, median (range) years | 52.3 (20.2–64.0) | 51.3 (25.6–68.2)a |
Female gender, no. (%) | 14 (51.9) | 20 (55.6) |
CMV serostatus, no. (%)b | ||
+ | 10 (37.0) | 21 (58.3) |
- | 17 (63.0) | 9 (25.0) |
Donor (D)/Recipient (R) CMV serostatus, no. (%) | ||
D+/R+ & D−/R+ | 21 (58.3) | |
D+/R- | 3 (8.3) | |
D−/R- | 12 (33.3) | |
Temporary (val) ganciclovir, no. (%)c | 8 (22.2) | |
Cause of renal failure, no. (%) | ||
Glomerulonephritis | 15 (41.7) | |
IgA nephropathy | 9 (25.0) | |
MPGN | 2 (5.6) | |
FSGS | 2 (5.6) | |
Anti-GBM | 1 (2.8) | |
SLE | 1 (2.8) | |
Vascular | 3 (8.3) | |
Diabetic nephropathy | 3 (8.3) | |
Genetic | 4 (11.1) | |
Urologic | 3 (8.3) | |
Congenital | 1 (2.8) | |
Chronic TIN | 1 (2.8) | |
Unknown | 6 (16.7) | |
Immunosuppression | ||
Tac/MMF/Pred | 29 (80.6) | |
Cyc/MMF/Pred | 4 (11.1) | |
Tac/MMF/Pred to Cyc/MMF/Predd | 2 (5.6) | |
Everolimus/MMF/Pred | 1 (2.8) | |
History of > 1 Tx, no. (%) | 6 (16.7) | |
RRT pre-Tx, no. (None/HD/PD) | 9/16/11 | |
Pre-Tx lymphocytes, × 109 cells/l, median (IQR)e | 1.7 (1.2–2.2) | |
Rejection | 6 (16.7) | |
Infection, any/bacterial/viral | 28/16/21 | |